XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues $ 53,165 $ 58,749 $ 103,810 $ 109,202 $ 103,810 $ 109,202
Consumables [Member] | Transferred at Point in Time [Member]            
Revenues 29,685 31,968 57,156 60,245    
Hardware and Software [Member] | Transferred at Point in Time [Member]            
Revenues 13,953 16,580 27,230 28,894    
Service [Member] | Transferred at Point in Time [Member]            
Revenues 9,527 10,201 19,424 20,063    
Operating Segments [Member] | Sterilization and Disinfection Control [Member]            
Revenues 17,080 [1] 16,964 [1] 33,007 31,738 33,007 [1] 31,738 [1]
Operating Segments [Member] | Clinical Genomics [Member]            
Revenues 15,549 [1] 18,435 [1] 28,918 32,940 28,918 [1] 32,940 [1]
Operating Segments [Member] | Biopharmaceutical Development [Member]            
Revenues 9,207 [1] 12,144 [1] 19,096 23,111 19,096 [1] 23,111 [1]
Operating Segments [Member] | Calibration Solutions [Member]            
Revenues 11,329 [1],[2] 11,206 [1],[2] 22,789 [2] 21,413 [2] $ 22,789 [1] $ 21,413 [1]
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]            
Revenues 14,749 14,704 28,456 26,932    
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]            
Revenues 9,963 12,399 18,732 23,930    
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]            
Revenues 4,187 4,000 8,673 7,664    
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]            
Revenues 786 865 1,295 1,719    
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]            
Revenues 120 218 201 524    
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]            
Revenues 4,474 4,394 7,901 5,885    
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]            
Revenues 2,475 5,988 5,166 10,812    
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]            
Revenues [2] 6,884 5,980 13,962 11,673    
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]            
Revenues 2,211 2,042 4,350 4,282    
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]            
Revenues 1,112 1,642 2,285 3,125    
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]            
Revenues 2,545 2,156 5,257 4,635    
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]            
Revenues [2] $ 3,659 $ 4,361 $ 7,532 $ 8,021    
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.